A new take on prions: preventing Alzheimer's disease

Trends in Biochemical Sciences

Volumn 33, Issue 4, 2008, Pages 151-155

  Hooper, Nigel M ^a   Turner, Anthony J ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA SECRETASE; GLYCOSAMINOGLYCAN; PRION PROTEIN;

ALZHEIMER DISEASE; ARTICLE; CREUTZFELDT JAKOB DISEASE; DNA POLYMORPHISM; GENETIC RISK; GERSTMANN STRAUSSLER SCHEINKER SYNDROME; HOMOZYGOSITY; HUMAN; NONHUMAN; OUTCOME ASSESSMENT; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN INTERACTION; SOCIOECONOMICS;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ASPARTIC ENDOPEPTIDASES; CREUTZFELDT-JAKOB SYNDROME; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MEMBRANE MICRODOMAINS; MODELS, BIOLOGICAL; MODELS, THEORETICAL; PRION DISEASES; PRIONS; RECEPTORS, CELL SURFACE;

EID: 41549165086     PISSN: 09680004     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tibs.2008.01.004     Document Type: Article

References (50)

1. Wimo A., et al. An estimate of the total worldwide societal costs of dementia in 2005. Alzheimer's & Dementia 3 (2007) 81-91
2. Hodes R.J. Public funding for Alzheimer disease research in the United States. Nat. Med. 12 (2006) 770-773
3. Roberson E.D., and Mucke L. 100 years and counting: prospects for defeating Alzheimer's disease. Science 314 (2006) 781-784
4. Aguzzi A., et al. Prions: health scare and biological challenge. Nat. Rev. Mol. Cell Biol. 2 (2001) 118-126
5. Llewelyn C.A., et al. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet 363 (2004) 417-421
6. Wroe S.J., et al. Clinical presentation and pre-mortem diagnosis of variant Creutzfeldt-Jakob disease associated with blood transfusion: a case report. Lancet 368 (2006) 2061-2067
7. Mattson M.P. Pathways towards and away from Alzheimer's disease. Nature 430 (2004) 631-639
8. Hetz C., et al. Is loss of function of the prion protein the cause of prion disorders?. Trends Mol. Med. 9 (2003) 237-243
9. Leuba G., et al. Early-onset familial Alzheimer disease with coexisting beta-amyloid and prion pathology. JAMA 283 (2000) 1689-1691
10. Tsuchiya K., et al. Coexistence of CJD and Alzheimer's disease: an autopsy case showing typical clinical features of CJD. Neuropathology 24 (2004) 46-55
11. Dermaut B., et al. PRNP Val129 homozygosity increases risk for early-onset Alzheimer's disease. Ann. Neurol. 53 (2003) 409-412
12. Riemenschneider M., et al. Prion protein codon 129 polymorphism and risk of Alzheimer disease. Neurology 63 (2004) 364-366
13. Golanska E., et al. Polymorphisms within the prion (PrP) and prion-like protein (Doppel) genes in AD. Neurology 62 (2004) 313-315
14. Bertram L., et al. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat. Genet. 39 (2007) 17-23
15. Checler F., and Vincent B. Alzheimer's and prion diseases: distinct pathologies, common proteolytic denominators. Trends Neurosci. 25 (2002) 616-620
16. Barnham K.J., et al. Delineating common molecular mechanisms in Alzheimer's and prion diseases. Trends Biochem. Sci. 31 (2006) 465-472
17. Parkin E.T., et al. Cellular prion protein regulates β-secretase cleavage of the Alzheimer's amyloid precursor protein. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 11062-11067
18. Andersen O.M., et al. Neuronal sorting protein-related receptor sorLA/LR11 regulates processing of the amyloid precursor protein. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 13461-13466
19. Jankowsky J.L., et al. Rodent Aβ modulates the solubility and distribution of amyloid deposits in transgenic mice. J. Biol. Chem. 282 (2007) 22707-22720
20. c) promotes β-amyloid plaque formation. Neurobiol. Aging 26 (2005) 1177-1182
21. Warner R.G., et al. Identification of the heparan sulfate binding sites in the cellular prion protein. J. Biol. Chem. 277 (2002) 18421-18430
22. Pan T., et al. Cell-surface prion protein interacts with glycosaminoglycans. Biochem. J. 368 (2002) 81-90
23. Cordy J.M., et al. The involvement of lipid rafts in Alzheimer's disease. Mol. Membr. Biol. 23 (2006) 111-122
24. Taylor D.R., and Hooper N.M. The prion protein and lipid rafts. Mol. Membr. Biol. 23 (2006) 89-99
25. Taylor D.R., et al. Assigning functions to distinct regions of the N-terminus of the prion protein that are involved in its copper-stimulated, clathrin-dependent endocytosis. J. Cell Sci. 118 (2005) 5141-5153
26. Walmsley A.R., et al. Membrane topology influences N-glycosylation of the prion protein. EMBO J. 20 (2001) 703-712
27. Abad-Rodriguez J., et al. Neuronal membrane cholesterol loss enhances amyloid peptide generation. J. Cell Biol. 167 (2004) 953-960
28. Rezaie P., et al. Expression of cellular prion protein in the frontal and occipital lobe in Alzheimer's disease, diffuse Lewy body disease, and in normal brain: an immunohistochemical study. J. Histochem. Cytochem. 53 (2005) 929-940
29. Fukumoto H., et al. β-secretase protein and activity are increased in the neocortex in Alzheimer disease. Arch. Neurol. 59 (2002) 1381-1389
30. Yang L.B., et al. Elevated β-secretase expression and enzymatic activity detected in sporadic Alzheimer disease. Nat. Med. 9 (2003) 3-4
31. Finckh U., et al. High prevalence of pathogenic mutations in patients with early-onset dementia detected by sequence analyses of four different genes. Am. J. Hum. Genet. 66 (2000) 110-117
32. Kitamoto T., et al. An amber mutation of prion protein in Gerstmann-Straussler syndrome with mutant PrP plaques. Biochem. Biophys. Res. Commun. 192 (1993) 525-531
33. Ghetti B., et al. Vascular variant of prion protein cerebral amyloidosis with tau- positive neurofibrillary tangles: the phenotype of the stop codon 145 mutation in PRNP. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 744-748
34. Bueler H., et al. Normal development and behaviour of mice lacking the neuronal cell-surface PrP protein. Nature 356 (1992) 577-582
35. Manson J.C., et al. 129/Ola mice carrying a null mutation in PrP that abolishes mRNA production are developmentally normal. Mol. Neurobiol. 8 (1994) 121-127
36. Bishop M.T., et al. Predicting susceptibility and incubation time of human-to-human transmission of vCJD. Lancet Neurol. 5 (2006) 393-398
37. Yokoyama T., et al. In vivo conversion of cellular prion protein to pathogenic isoforms, as monitored by conformation-specific antibodies. J. Biol. Chem. 276 (2001) 11265-11271
38. Prusiner S.B. Prions. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 13363-13383
39. Krasemann S., et al. Prion disease associated with a novel nine octapeptide repeat insertion in the PRNP gene. Brain Res. Mol. Brain Res. 34 (1995) 173-176
40. Hegde R.S., et al. A transmembrane form of the prion protein in neurodegenerative disease. Science 279 (1998) 827-834
41. Cashman N.R., and Caughey B. Prion diseases-close to effective therapy?. Nat. Rev. Drug Discov. 3 (2004) 874-884
42. Mallucci G., and Collinge J. Rational targeting for prion therapeutics. Nat. Rev. Neurosci. 6 (2005) 23-34
43. Mallucci G.R., et al. Post-natal knockout of prion protein alters hippocampal CA1 properties, but does not result in neurodegeneration. EMBO J. 21 (2002) 202-210
44. Sc propagation in prion-infected cells. J. Biol. Chem. 278 (2003) 18524-18531
45. Sc replication in infected cells. J. Biol. Chem. 280 (2005) 11247-11258
46. Heppner F.L., et al. Prevention of scrapie pathogenesis by transgenic expression of anti-prion protein antibodies. Science 294 (2001) 178-182
47. White A.R., et al. Monoclonal antibodies inhibit prion replication and delay the development of prion disease. Nature 422 (2003) 80-83
48. Haass C. Take five-BACE and the γ-secretase quartet conduct Alzheimer's amyloid β-peptide generation. EMBO J. 23 (2004) 483-488
49. Vardy E.R., et al. Emerging therapeutics for Alzheimer's disease. Expert Rev. Neurother. 6 (2006) 695-704
50. Allinson T.M., et al. ADAMs family members as amyloid precursor protein α-secretases. J. Neurosci. Res. 74 (2003) 342-352